BDF Gestion Has $4 Million Holdings in Stryker Co. (NYSE:SYK)

BDF Gestion trimmed its holdings in Stryker Co. (NYSE:SYK) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,116 shares of the medical technology company’s stock after selling 1,444 shares during the quarter. BDF Gestion’s holdings in Stryker were worth $4,002,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Planning LLC lifted its stake in Stryker by 3.6% in the fourth quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after buying an additional 29 shares in the last quarter. Alhambra Investment Management LLC boosted its position in Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the period. Avestar Capital LLC boosted its stake in shares of Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock valued at $1,065,000 after purchasing an additional 31 shares during the last quarter. Union Savings Bank boosted its holdings in shares of Stryker by 1.0% during the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after buying an additional 31 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. grew its stake in Stryker by 1.5% in the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock valued at $793,000 after acquiring an additional 32 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 1.1 %

NYSE:SYK opened at $390.98 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 1 year low of $314.05 and a 1 year high of $406.19. The stock has a market cap of $149.05 billion, a price-to-earnings ratio of 41.91, a PEG ratio of 2.68 and a beta of 0.95. The business has a fifty day moving average of $376.44 and a 200-day moving average of $361.98.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter last year, the business posted $3.46 earnings per share. Equities analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is presently 36.01%.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Evercore ISI increased their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $413.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.